Navigation Links
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
Date:4/22/2008

NEW YORK, April 22 /PRNewswire/ -- Some of the biggest-selling biologics developed during the boom years in biotech of the 1980's, including human growth hormone (hGH) and insulin, have lost patent protection in the U.S. in 2007 or will shortly, and they represent a market of $40 billion. This opens up a huge potential market for biosimilars, if regulatory hurdles can be overcome, according to a new report by Kalorama Information, Biogenerics: the World Market for Biosimilars.

Worldwide interest in biosimilars is gaining momentum and is expected to reach $5.8 billion by 2012. But first such stumbling blocks as safety, access to innovators' key intermediates, process controls, availability and access to bulk materials, specifically designed and adapted analytical procedures and validation studies must be addressed. Also, biosimilars cannot currently be marketed in the U.S. because there is no pathway for them to reach the market.

"Right now, there is limited competition in biosimilars due to the complicated regulatory process and the high costs," notes Mary Anne Crandall, senior analyst for Kalorama. "But this won't last forever, and in fact in the near-term we should see some technological changes and political shifts that will fuel the market."

Biosimilars have been selling outside of the U.S. for years, creating a small existing market. As the industry is allowed in the U.S., which Kalorama predicts will happen in a serious way by 2009, it will grow exponentially. Growth will likely occur around a few big biopharmaceuticals at first.

Kalorama Information's report Biogenerics: the World Market for Biosimilars identifies the biopharmaceuticals that have lost patent protection and are likely to be the first products attempted by generic companies. Current and future trends, market size and projections are also provided. The report can be purchased directly from Kalorama Information by visiting

SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... The long-awaited speaking faculty for the September Pharma ... the conference website reports Mark Alexay, President of ... is comprised of 100 speakers from pharmaceutical companies ... in the pipeline. The speaker list may be ...
... of Avastin Will Take Market Share Away from ... New Report from Decision ResourcesWALTHAM, Mass., March 10 ... research and advisory firms for pharmaceutical and healthcare ... in the age-related macular degeneration (AMD) market through ...
... March 10 Christine Lawless, MD, has ... an ACCME-accredited provider of continuing medical education (CME), beginning ... leading authorities in sports medicine cardiology, Dr. Lawless recently ... University Medical Center, where she was Associate Professor ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2
(Date:7/11/2014)... TRAP" to capture the early signs of kidney failure, ... Journal of Clinical Investigation . Their new transgenic ... cellular and genetic information from a variety of solid ... for Medical Research in 2008, TRAP involves attaching a ... the cell type of interest. Scientists can then collect ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... to an Asian bark fungus accidentally introduced to the United ... was highly valued for its strong, workable lumber and a ... upon the chestnut for food. Ongoing efforts to reintroduce ... because they rely on genetic cross breeding to produce ...
... the United States have collaborated to complete the first ... called miscanthus. The results published in the current ... provide a significant breakthrough towards advancing the ... the long-term collaboration between energy crop company Ceres, Inc., ...
... line defence of the brain and are constantly looking ... uncontrolled inflammation within the brain, which can in turn ... Central,s open access journal Journal of Neuroinflammation ... production of pro-inflammatory cytokines and inflammatory enzymes in activated ...
Cached Biology News:UC research tests new tool to guide reintroduction of the American chestnut 2UC research tests new tool to guide reintroduction of the American chestnut 3First complete full genetic map of promising energy crop 2First complete full genetic map of promising energy crop 3The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage 2
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
...
Biology Products: